NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceGlobeNewsWire • 11/06/23
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/20/23
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceGlobeNewsWire • 08/08/23
NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock MarketGlobeNewsWire • 07/19/23
NeuroPace, Inc. (NPCE) CEO Michael Favet on Q1 2023 Results - Earnings Call TranscriptSeeking Alpha • 05/07/23
NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceGlobeNewsWire • 05/04/23
NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/03/23
NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023GlobeNewsWire • 02/10/23
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of DirectorsGlobeNewsWire • 01/09/23
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now UnderwayBusiness Wire • 11/30/22
Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 Results24/7 Wall Street • 11/23/22